S E T T I N G : Multidrug-resistant tuberculosis (MDR-TB
TUBERCULOSIS (TB) is one of the leading infectious causes of adult deaths globally, accounting for an estimated 1.7 million deaths each year. Multidrugresistant tuberculosis (MDR-TB), defi ned as strains of TB with in vitro resistance to isoniazid (INH) and rifampin (RMP), is a form of the disease that has rising morbidity and mortality. The treatment of MDR-TB is more complex than for pan-susceptible disease, requiring multiple second-line anti-tuberculosis agents given over a period of 18-24 months. 1 One of the main concerns about MDR-TB regimens is their potential for causing adverse effects, particularly in vulnerable populations. [2] [3] [4] [5] The development of hepatotoxicity-including hepatitis (hepatocellular necrosis), cholestasis (impairment of bile fl ow), and zonal necrosis-is one of the most commonly reported adverse effects associated with fi rst-and second-line anti-tuberculosis treatment. 6, 7 Rates of hepatotoxicity of between 1% and 80%-with varying defi nitions used to defi ne the condition-have been reported in patients undergoing treatment for TB and MDR-TB. [8] [9] [10] [11] In the case of anti-tuberculosis treatment, a number of fi rst-and second-line anti-tuberculosis drugs have been implicated as potential causative agents of drug-induced liver injury (DILI; Table 1 ). Patient responses to DILI can be idiosyncratic, and can range from simple adaptation with no further negative effect to fulminant hepatitis and death. 27 The use of alcohol is often considered to be a major predisposing risk factor for the development of hepatitis among patients on anti-tuberculosis treatment, [28] [29] [30] as is co-infection with the human immunodefi ciency virus (HIV) or viral hepatitides. [31] [32] [33] [34] [35] [36] This is of particular concern in the setting of the former Soviet Union, where rates of alcoholism and injecting drug use are high. [37] [38] [39] In the present study, we describe the incidence and management of hepatotoxic events during MDR-TB treatment in a cohort of patients in Tomsk, Russia, and assess risk factors associated with the occurrence of this adverse event. We also explore
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whether the development of hepatotoxicity after the commencement of treatment was associated with poor treatment outcome.
METHODS
Setting
Tomsk Oblast (population in 2006: 1 036 000) is located in western Siberia, in the Russian Federation. Between 1993 and 2000, the tuberculosis notifi cation rate in Tomsk increased from 80.6 per 100 000 population to 116.7, an estimated 15-20% of which were MDR-TB (Tomsk Oblast Tuberculosis Services, unpublished data). In the face of this growing epidemic, 40, 41 in 2000 Tomsk Oblast expanded its TB program to include the treatment of MDR-TB.*
Study design
This was a retrospective case series of 608 patients with confi rmed MDR-TB at baseline enrolled for MDR-TB treatment between 10 September 2000 and 1 November 2004. Patients were included if they had active TB evidenced by positive culture and drug susceptibility testing (DST) results showing MDR-TB. † There were no exclusion criteria. Treatment regimens were designed using a standard algorithm. 1, 42, 43 Patients received quality-assured second-line anti-tuberculosis drugs procured through the Green Light Committee. 44 Patient management and treatment outcomes of this cohort have been reported elsewhere. 45 Laboratory data, including serum potassium, liver function tests, creatinine, and thyroid stimulating hormone, were monitored at least monthly. Physicians reported adverse reactions and management-according to protocols disseminated in training courses-using a realtime reporting form. 43 Patient charts were reviewed retrospectively. Laboratory data were electronically imported into the study database.
All patients initiating TB treatment in Tomsk are routinely tested for HIV infection. Alcohol use and illicit drug use were considered to be present if documented by the treating physician in the patient chart. Baseline alcohol use was defi ned as a recording of a diagnosis of 'alcoholism' at intake by a physician or mental health provider. Use during treatment was defi ned as recording of patient intoxication in the chart. 'Hepatoxicity' was defi ned as per the 2006 American Thoracic Society guidelines: documented elevations of either transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) and/or bilirubin above fi ve times the upper limit of normal (ULN) at any point after commencing treatment, or three times the ULN with either recorded clinical symptoms or a change of more than twice the baseline levels. 27, 46 'Baseline hepatitis' was defi ned as laboratory results showing signs of hepatotoxicity within 60 days prior to treatment commencement and/or a clinical diagnosis from the admitting physician. Tests for hepatitis B and hepatitis C were performed among the majority of patients in the second patient cohort. ‡ Other comorbid conditions, such as chronic renal insuffi ciency, diabetes mellitus, and seizure disorder, were considered to be present if documented in the patient chart by a physician. Low body mass index (BMI) was defi ned as <18.5 kg/m 2 for women and <20 for men. 47 Nonadherence to treatment was defi ned as missing more than 20% of the prescribed doses (a dose was defi ned as any single administration of all prescribed medications) during the entire treatment period. Treatment outcomes were defi ned according to international consensus defi nitions. 48 'Good' outcomes were defi ned as cure or treatment completion. 'Poor' treatment outcomes were defi ned as default, failure, or death from any cause during MDR-TB treatment.
Continuous data were assessed for normality using a skewness-kurtosis test. Univariable and multivariable logistic regression were conducted to assess factors associated with good treatment outcomes. A fi nal model was determined using likelihood ratio testing. Variables included in the multivariable analysis were assessed for interaction and effect modifi cation. Base- line drug regimens were assessed using the fi rst regimen assigned to each patient within the study time frame. Drug regimens at the time of the fi rst episode of hepatotoxicity were assessed using the closest documented regimen on or prior to the laboratory date. If no regimen was listed prior to the laboratory date, the baseline regimen was assumed to be the regimen the patient was on at the time of elevated transaminases/bilirubin.
RESULTS
Laboratory data were unavailable for 40 patients, who were not included in the analysis. These 40 patients were not signifi cantly different from the remaining cohort with respect to treatment outcomes (data not shown). The analysis was performed among the remaining 568 individuals. Properties and characteristics of the cohort as a whole and those developing hepatotoxicity during treatment vs. those who did not are presented in Table 2 . This was a young, predominantly male (82%) population, with very low rates of HIV co-infection (0.7%); 28% of the cohort started treatment within the prison system. As could be expected, this cohort consisted of very ill people: 60% had both bilateral and cavitary disease, and 43% had low BMI at baseline. Only 13 people (2.3%) in the cohort had baseline hepatitis. Ninety-one patients (16.5%) developed hepatotoxicity during treatment. , although the numbers were small (n = 13 and n = 5, respectively) and the CIs were wide (Table 4) . We also looked at the subset of individuals who had been tested for viral hepatitis. Of 327 patients, 281 (85.9%) were tested for hepatitis B or C, or both. Of these, 21 (7.5%) tested positive for hepatitis B, 43 (15.3%) were positive for hepatitis C, and 13 (4.6%) were positive for both. Among all patients tested for hepatitis, 48 (17.4%) developed hepatotoxicity during MDR-TB treatment. Baseline diagnosis of hepatitis C showed a trend towards association with the development of hepatoxicity, with borderline statistical signifi cance (OR 2.19, 95%CI 0.99-4.98).
Univariable analysis of the full cohort (Table 5) found that good treatment outcome was associated Figure Time to first hepatotoxic event (n = 91). Table 7 ).* Information was available for treatment regimen just prior to fi rst recorded elevated transaminases/bilirubin for 85/91 patients (Table 6 ). Of these 91 patients, 31 (34%) had an unanticipated change made to their regimens within 45 days after the date of detection of elevated liver enzymes. Ten patients had one or more drugs permanently dropped from the regimen specifi cally because of hepatitis or elevated transaminases; in none of these cases was treatment entirely discontinued due to hepatotoxicity (Table 8). The drugs most often stopped permanently by clinicians were pyrazinamide (PZA) and ethionamide (ETH)/prothionamide (PTH).
Other management strategies included the use of ancillary medications and supportive care to control symptoms of side effects, such as nausea or dehydration. In addition, 'hepato-protectors' were ubiquitously used (not only among those experiencing hepatotoxicity) in this cohort. These include 'karsil' and 'hepatoprotektor', which are commonly used in Russian medicine, 49, 50 although no clinical benefi t of these agents has been demonstrated.
DISCUSSION
The treatment of MDR-TB using currently available tools is clinically complex and challenging. Clinicians treating patient populations with a high prevalence of concomitant alcohol use during treatment and/or viral hepatitis face additional concerns about adverse events from the use of some fi rst-and second-line anti-tuberculosis drugs. In patients with baseline hepatitis and those who develop hepatotoxicity during * Interestingly, for patients who did use alcohol, development of hepatotoxicity was associated with good outcomes (OR 4.40, 95%CI 1.79-10.81) compared to those who did not develop hepatotoxicity. Patients who did not develop elevated transaminases/bilirubin during treatment presented a different picture: in multivariable analysis, alcohol use, smoking history, bilateral and cavitary disease at baseline and respiratory insuffi ciency at baseline were associated with worse treatment outcomes. High levels of treatment adherence were associated with good outcomes. * Drugs were permanently stopped in 10 patients based on the clinician's assessment of toxicity. † Drugs in regimen within 2 weeks of laboratory hepatotoxic event if listed in chart (n = 85). If no regimen was listed (n = 6), the last documented regimen was used. PAS = para-aminosalicylic acid.
601 treatment, physicians should seriously weigh the dangers of continued treatment vs. intermittently treated or untreated MDR-TB. In this study of MDR-TB treatment in Tomsk, Russia, in a patient population with high alcohol use, and presence of both hepatitis B and C, hepatotoxicity was not, in general, associated with poor treatment outcomes. In many ways, these fi ndings are expected. Watkins describes 'adaptation' among patients with drug-induced transaminitis upon continued exposure to the drug. 51 Management of hepatotoxicity in patients with TB can be complicated. As patients receive multidrug regimens, it can be diffi cult to pinpoint the precise agent responsible for the hepatotoxic effects. 52 Some studies have found that gradually re-introducing the medications or re-introducing them in a stepwise fashion leads to less repeat hepatotoxicity, although most data have been limited to individuals without MDR-TB. 53 To date, few data are available on how to manage adverse events among MDR-TB patients, in particular whether to suspend any or all anti-tuberculosis agents and how to re-instate these medications. As with management of pan-susceptible TB, there are often several potential offenders, and identifi cation of the culprit drug requires sequential re-initiation of anti-tuberculosis drugs. In general, the management approach to hepatotoxicity adopted by this community of Tomsk physicians was to suspend all medications and, once liver function tests normalized, to initiate the anti-tuberculosis drugs one by one, saving the most likely offenders for the end. Such an approach enabled the physicians to reinstate the full MDR-TB regimen in the vast majority of hepatoxicity cases. In the 10 patients in whom medications were stopped, PZA and/or ETH/PTH were the most frequent agents selected, a fi nding consistent with the literature (Table 1) . Importantly, none of these cases required complete discontinuation of MDR-TB treatment. This is especially important for MDR-TB patients, for whom few therapeutic options may be available and for whom continuation of appropriate multi-drug regimens is critical. In this cohort, such an aggressive approach in the management of hepatotoxicity, even among individuals with chronic viral hepatitis and active alcohol users, resulted in fi nal treatment outcomes that were comparable to those among individuals without hepatoxicity.
Patients experienced hepatotoxic events quite late in their treatment (mean = 196 days). In general, patients were hospitalized for the early 4-6 months of treatment, after which they received ambulatory treatment. The hepatotoxicity observed during this period may have been linked to increased access to alcohol. This is an area that will require further study.
The fi nding that alcohol use during treatment was associated with poor treatment outcome among those who did not experience hepatotoxicity, but was not associated with poor outcome in people with hepatotoxicity, may refl ect an increased level of health system attention to patients with this side effect. If this is the case, then it supports the contention that being closely followed by health workers can lead to a mitigation of the negative biological and social effects of alcohol on successful TB treatment. 54 However, the alcohol use variable was imprecise; any documentation of intoxication was suffi cient to be included as a drinker. If alcohol use was overestimated in those with hepatotoxicity, but not in those without, this fi nding might be refl ective of bias, and the well-known negative effects of alcohol use on outcome underestimated.
Cigarette smoking history and more severe illness (bilateral and cavitary disease) were also associated with poorer treatment outcomes, after controlling for alcohol use and other factors. Although smokers were no more likely to have respiratory insuffi ciency at baseline than non-smokers, they were more likely to die or fail treatment than non-smokers (data not shown). These fi ndings for patients with MDR-TB corroborate published data that cigarette smoking is associated with poor treatment outcomes in the treatment of drug-susceptible disease. 55, 56 Our study does have several important limitations. First, as mentioned above, assessment of alcohol use was imprecise, and based on the physician documenting intoxication in the chart, and did not allow for assessment of quantity or duration of alcohol use or time relationships to the hepatotoxic events. Second, tests for hepatitis B and C were not collected for the early cohort of patients. Small numbers may have precluded measurement of the true effect of this comorbidity, as this was not an outcome the original protocol was powered to detect. Another limitation of the study is that we only followed the patients during treatment and were therefore unable to assess whether those with hepatotoxicity had longer-term health problems secondary to this. Strengths of the study include the fact that adverse events and treatment adherence data were captured prospectively, and our assessment of hepatitis is based on laboratory confi rmation.
